Moe Myint Oo’s Post

🌟 Exciting News! 🌟 I'm happy to share my latest editorial titled "Advances in Liquid Biopsy Research for Disease Detection, Diagnosis, and Treatment and What the Future May Hold". 📝💡 In this editorial, I delve into the latest innovations shaping the landscape of liquid biopsy research. 💉 From early disease detection to personalized treatment strategies, discover how liquid biopsies are revolutionizing healthcare. 🩺✨ Click the link below to read more! 👇 #LiquidBiopsy #Research #HealthcareInnovation #FutureMedicine https://lnkd.in/ebKUeWaq

Ensuring your voice is heard loud and clear is one of our priorities. Yesterday, Jo Lowe from ASIF, represented people living with #axSpA at a Patient Leader Workshop focused on #biosimilar treatments. The workshop emphasised the breadth of information that people taking biosimilars need to know and understand, as well as the importance of shared decision-making.     Today, Jo will attend the 20th edition of the Biosimilar Medicines Conference in Amsterdam where sessions will cover biosimilar health economy and policy; and seek to find better ways to address some of the challenges in developing of biosimilars.    #axialspondyloarthritis #BIOS24

Our latest report analyses patient opinions on #NHSdiagnostics based on a survey we ran in partnership with Roche Diagnostics UK & Ireland. We'll be exploring the findings at a webinar on 5th March. Sign up for free. 🔗https://ow.ly/juTa50QIchY Key findings include: • Three out of five (60%) would consider paying privately to avoid long waits. • More than nine out of ten (93%) want more investment in testing capacity. • More than three in four (77%) would be happy to test themselves at home. • Almost nine out of ten (88%) want a realistic timeframe for their test results to come through.

Recently, we joined the United Nations Institute for Training and Research (UNITAR) in hosting a roundtable with representatives from the global healthcare and patient communities to discuss the role of plasma-derived therapies in global healthcare and the need to urgently tackle barriers to plasma products worldwide. Learn more about this important discussion by watching the roundtable: https://lnkd.in/dexAvefU

As healthcare shifts to become more patient centric, it’s more important than ever for pharma companies to identify which levers they need to activate as part of the launch strategy. In this on-demand demo, our experts dive into the complexities associated with drug launches, discuss common challenges across rare diseases and show how ZAIDYN™ Health Insights can bolster your understanding of the market landscape to pinpoint winning strategies. https://bit.ly/3xKuW1m

As healthcare shifts to become more patient centric, it’s more important than ever for pharma companies to identify which levers they need to activate as part of the launch strategy. In this on-demand demo, our experts dive into the complexities associated with drug launches, discuss common challenges across rare diseases and show how ZAIDYN™ Health Insights can bolster your understanding of the market landscape to pinpoint winning strategies. https://bit.ly/4f0sMLB

CARB-X Executive Director Kevin Outterson presented on the urgency of implementing incentives to stimulate antibacterial R&D based on CARB-X’s experience at the House Budget Committee’s bipartisan roundtable titled, “Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance and the Broken Antibiotic Development Pipeline.” The roundtable recognized how the growing health threat of antimicrobial resistance, combined with a shrinking drug development pipeline, threatens modern medicine and will drive up federal healthcare spending. “I would far rather practice in a time when antimicrobials are available than a time when they were not available. We're here to explore innovative solutions. Our commitment is to collaborate to curb antimicrobial resistance, and protecting future generations in this crucial endeavor,” said House Budget Committee Health Care Task Force Chairman Michael C. Burgess, MD, (R-TX) in a press release. 🔗 Read the House Budget Committee’s full press release here: bit.ly/46u6wG7 #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #HouseBudgetCommittee

We welcome the recommendations put forth during the AMR Industry Alliance Call-to-Action in New York, particularly the emphasis on enhancing the responsible use of antimicrobials by prioritizing diagnostics through improved valuation and investment in diagnostics. Dive into the comprehensive report of these impactful recommendations: https://lnkd.in/d7BnW73A #AMR #AntimicrobialResistance #HealthcareInnovation

As healthcare shifts to become more patient centric, it’s more important than ever for pharma companies to identify which levers they need to activate as part of the launch strategy. In this on-demand demo, our experts dive into the complexities associated with drug launches, discuss common challenges across rare diseases and show how ZAIDYN™ Health Insights can bolster your understanding of the market landscape to pinpoint winning strategies. https://bit.ly/4cEUYSI

CARMA Latest Media Analysis Report: Monkeypox Crises Gain key insights into the media landscape surrounding monkeypox. Our comprehensive analysis explores pharma and health agencies discussions, public sentiment, and evolving narratives across global channels. Stay informed and strategize effectively with data-backed findings that matter. #MediaAnalysis #Monkeypox #PublicHealth #PRStrategies ##pharmaceutical #CARMA https://lnkd.in/d9YC4Kw3